<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961632</url>
  </required_header>
  <id_info>
    <org_study_id>TCF20-BRE-01</org_study_id>
    <nct_id>NCT04961632</nct_id>
  </id_info>
  <brief_title>Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376</brief_title>
  <official_title>An Open-label, Single-institution, Dose-determining (Part 1) and Dose-confirmatory (Part II) Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients Harboring Different TCF20 rs932376 Variant Alleles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Medical Research Council (NMRC), Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that the TCF20 rs932376 locus controls endoxifen levels in&#xD;
      estrogen receptor (ER)-positive breast cancer patients on tamoxifen therapy and that the&#xD;
      requirement of tamoxifen dose to achieve therapeutic levels of endoxifen varies according to&#xD;
      the genotype status of the patient's at the TCF20 rs932376 locus.&#xD;
&#xD;
      Patients will receive escalating doses of tamoxifen according to their TCF20 rs932376&#xD;
      genotype status. Patients on 20mg tamoxifen daily for 8 weeks or longer will provide blood&#xD;
      samples for analysis of tamoxifen and its metabolites. Patients assess with &gt;30nM endoxifen&#xD;
      concentrations will continue with 20mg tamoxifen dose. Patients who have endoxifen&#xD;
      concentrations &lt;30nM will receive dose increments of 10mg every 8 weeks until they achieve&#xD;
      endoxifen threshold of &gt;30nM or reach maximum dose level of 40mg/day.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoxifen blood concentration</measure>
    <time_frame>8 weeks after each tamoxifen dose level at 20mg, 30mg and 40mg</time_frame>
    <description>To determine the optimal dose of tamoxifen required to achieve therapeutic endoxifen levels for each TCF20 rs932376 genotype group in the dose-determination phase</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dose-determination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-confirmation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Patients taking 20mg tamoxifen will receive dose increments of 10mg every 8 weeks until endoxin threshold of &gt;30nM or the maximum dose of 40mg/day is reached. The escalated dose will be taken for 1 year before reverting back to 20mg.</description>
    <arm_group_label>Dose-determination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Patients will take tamoxifen at the ascribed genotype-determined dose as determined in the dose-determination phase.</description>
    <arm_group_label>Dose-confirmation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed stage I to IV breast cancer&#xD;
&#xD;
          -  Age greater than 21 years&#xD;
&#xD;
          -  Estrogen- or progesterone-receptor positive tumours&#xD;
&#xD;
          -  Patients receiving tamoxifen 20mg daily as monotherapy&#xD;
&#xD;
          -  Patients currently taking tamoxifen in either adjuvant or metastatic setting for&#xD;
             greater than or equal to 8 weeks (for Dose determination and confirmation phases)&#xD;
&#xD;
          -  Patients who will commence on tamoxifen therapy in either adjuvant or metastatic&#xD;
             setting (for Dose confirmation phase only)&#xD;
&#xD;
          -  Written and informed consent from participating patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with expected survival less than 6 months&#xD;
&#xD;
          -  Patients who are human epidermal growth factor receptor 2 (HER2)-postitive&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Patients receiving CYP2D6 inhibitors or inducers within the past four weeks from the&#xD;
             time of study enrollment. However, patients started in CYP2D6 inhibitors or inducers&#xD;
             after commencing on tamoxifen therapy will not be excluded from the study.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients with prior malignancies other than those who have received curative treatment&#xD;
             for basal cell carcinoma of the skin or carcinoma in situ of the uterine cervix&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/ social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Patients who have documented prior allergic reaction to tamoxifen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine Lim</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elaine Lim</last_name>
    <phone>+65 6436 8000</phone>
    <email>elaine.lim.hsuen@singhealth.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

